论文部分内容阅读
目的:比较单药吉西他滨与吉西他滨联合奥沙利铂治疗非小细胞肺癌的疗效。方法:将75例非小细胞肺癌随机分为两组,21例单纯应用吉西他滨化疗(单药组),54例采用吉西他滨联合奥沙利铂化疗(联合组),对其疗效及毒副反应进行观察。结果:单药组和联合组有效率分别为23.8%和40.7%(χ2=1.881,P>0.05),WBC减少总的发生率57.1%和55.6%(χ2=0.015,P>0.05),PLT减少总的发生率52.4%和35.2%(χ2=1.863,P>0.05)。结论:单药吉西他滨与吉西他滨联合奥沙利铂治疗非小细胞肺癌安全有效,后者在临床有效率方面优于前者,但是该差异无显著性。
OBJECTIVE: To compare the efficacy of gemcitabine plus gemcitabine plus oxaliplatin in the treatment of non-small cell lung cancer. Methods: Seventy-five patients with non-small cell lung cancer were randomly divided into two groups. 21 patients were treated with gemcitabine alone (single drug group) and 54 patients received gemcitabine combined with oxaliplatin plus chemotherapy (combination group) Observed. Results: The effective rates were 23.8% and 40.7%, respectively (χ2 = 1.881, P> 0.05). The overall incidence of WBC decreased 57.1% and 55.6% (χ2 = 0.015, P> 0.05) The overall incidence was 52.4% and 35.2% (χ2 = 1.863, P> 0.05). Conclusion: Gemcitabine alone and gemcitabine plus oxaliplatin are safe and effective in the treatment of non-small cell lung cancer. The latter is superior to the former in terms of clinical efficiency, but the difference is not significant.